已收盘 07-14 16:00:00 美东时间
0.000
0.00%
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 yearsThese data were presented at the
2025-03-31 14:53
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the
2023-06-27 20:25
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) was the recip...
2023-03-31 16:34
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) was the recip...
2023-03-13 17:13
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) was the targe...
2023-03-12 19:53
Flow Traders U.S. LLC bought a new position in shares of Alpha Healthcare Acqui...
2023-03-10 19:59
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) was the targe...
2023-01-20 18:22
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) was the recip...
2023-01-18 18:13
生物技术研发公司Carmell Therapeutics(CTCX.US)计划与SPAC Alpha Healthcare (ALPA.US)合并上市。
2023-01-05 20:16
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA – Get Rating) was the recip...
2022-08-11 21:51